Hq Spclt Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HQ SPCLT PHARMA, and when can generic versions of HQ SPCLT PHARMA drugs launch?
HQ SPCLT PHARMA has fourteen approved drugs.
There are six US patents protecting HQ SPCLT PHARMA drugs.
There are twelve patent family members on HQ SPCLT PHARMA drugs in nine countries and ninety-one supplementary protection certificates in fifteen countries.
Summary for Hq Spclt Pharma
International Patents: | 12 |
US Patents: | 6 |
Tradenames: | 16 |
Ingredients: | 11 |
NDAs: | 14 |
Drugs and US Patents for Hq Spclt Pharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hq Spclt Pharma | LINEZOLID | linezolid | SOLUTION;INTRAVENOUS | 207001-002 | Jul 7, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Hq Spclt Pharma | CALCIUM GLUCONATE IN SODIUM CHLORIDE | calcium gluconate | SOLUTION;INTRAVENOUS | 210906-002 | Oct 29, 2018 | RX | Yes | Yes | 10,130,646 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Hq Spclt Pharma | MAGNESIUM SULFATE IN PLASTIC CONTAINER | magnesium sulfate | INJECTABLE;INJECTION | 207350-005 | Dec 6, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hq Spclt Pharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 4,177,263 | ⤷ Try a Trial |
Hq Spclt Pharma | CISPLATIN | cisplatin | INJECTABLE;INJECTION | 018057-004 | Nov 8, 1988 | 4,177,263 | ⤷ Try a Trial |
Hq Spclt Pharma | ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER | esmolol hydrochloride | SOLUTION;INTRAVENOUS | 205703-001 | Apr 7, 2016 | 6,310,094*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Hq Spclt Pharma Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2017184188 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2014143845 | ⤷ Try a Trial |
Canada | 2906031 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hq Spclt Pharma Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2957286 | 2018/046 | Ireland | ⤷ Try a Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
0984957 | 122012000017 | Germany | ⤷ Try a Trial | PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812 |
2666774 | 31/2020 | Austria | ⤷ Try a Trial | PRODUCT NAME: RELEBACTAM, GEGEBENENFALLS IN DER FORM DES MONOHYDRATS, IMIPENEM UND CILASTATIN, GEGEBENENFALLS IN DER FORM DES NATRIUMSALZES.; REGISTRATION NO/DATE: EU/1/19/1420 (MITTEILUNG) 20200217 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.